T. Facchini

849 total citations
22 papers, 401 citations indexed

About

T. Facchini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, T. Facchini has authored 22 papers receiving a total of 401 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in T. Facchini's work include Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (7 papers) and Advanced Breast Cancer Therapies (4 papers). T. Facchini is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (7 papers) and Advanced Breast Cancer Therapies (4 papers). T. Facchini collaborates with scholars based in France, United States and Australia. T. Facchini's co-authors include Xavier Pivot, L. Chaigneau, Aimery de Gramont, Christophe Tournigand, Armelle Dufresne, Franck Sturtz, D Belpomme, S. Gauthier, Éric Pujade-Lauraine and P. Fargeot and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

T. Facchini

20 papers receiving 382 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Facchini France 9 303 129 90 77 44 22 401
Frances M. Palmieri United States 13 333 1.1× 141 1.1× 66 0.7× 95 1.2× 23 0.5× 20 457
Sandeep Sehdev Canada 13 272 0.9× 201 1.6× 122 1.4× 54 0.7× 28 0.6× 35 451
Doris Augustin Germany 11 221 0.7× 191 1.5× 82 0.9× 42 0.5× 19 0.4× 59 345
Brian M.J. Cantwell United Kingdom 12 236 0.8× 51 0.4× 83 0.9× 126 1.6× 39 0.9× 21 369
Paule Augereau France 11 224 0.7× 80 0.6× 133 1.5× 102 1.3× 31 0.7× 45 402
Tanja K. Froehlich Switzerland 8 341 1.1× 59 0.5× 76 0.8× 187 2.4× 60 1.4× 11 475
M. Clemons Canada 10 209 0.7× 176 1.4× 56 0.6× 55 0.7× 75 1.7× 24 478
Claudia Arce-Salinas Mexico 11 241 0.8× 177 1.4× 80 0.9× 138 1.8× 47 1.1× 25 448
Rabih Said United States 11 153 0.5× 118 0.9× 105 1.2× 118 1.5× 70 1.6× 33 390
Valeria Forestieri Italy 10 387 1.3× 245 1.9× 101 1.1× 85 1.1× 61 1.4× 24 536

Countries citing papers authored by T. Facchini

Since Specialization
Citations

This map shows the geographic impact of T. Facchini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Facchini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Facchini more than expected).

Fields of papers citing papers by T. Facchini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Facchini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Facchini. The network helps show where T. Facchini may publish in the future.

Co-authorship network of co-authors of T. Facchini

This figure shows the co-authorship network connecting the top 25 collaborators of T. Facchini. A scholar is included among the top collaborators of T. Facchini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Facchini. T. Facchini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Facchini, T., et al.. (2024). The effects of oil adjuvant on the degradation of spirotetramat and its metabolites in apple cultivation. Scientific Reports. 14(1). 24655–24655. 1 indexed citations
2.
Ganem, G., Éric-Charles Antoine, Chantal Touboul, et al.. (2016). Maintaining professional activity during breast cancer treatment. European Journal of Cancer Care. 25(3). 458–465. 7 indexed citations
3.
Ganem, G., H. Naman, Nadine Dohollou, et al.. (2013). Continuing to work while receiving cancer treatment: A financial or a symbolic issue?. Journal of Clinical Oncology. 31(15_suppl). 6603–6603. 1 indexed citations
4.
Eisenberger, Mario A., Anne‐Claire Hardy‐Bessard, Loı̈c Mourey, et al.. (2012). Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.. Journal of Clinical Oncology. 30(15_suppl). TPS4692–TPS4692. 5 indexed citations
5.
Freyer, Gilles, Mario Campone, Julien Péron, et al.. (2011). Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: Results of an observational study. Critical Reviews in Oncology/Hematology. 80(3). 466–473. 28 indexed citations
6.
Curtit, Elsa, Nadine Dohollou, E. Lévy, et al.. (2011). Myotax: A phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. European Journal of Cancer. 47(16). 2396–2402. 9 indexed citations
7.
Dufresne, Armelle, Xavier Pivot, Christophe Tournigand, et al.. (2008). MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER. International Journal of Medical Sciences. 5(2). 100–105. 26 indexed citations
8.
Dufresne, Armelle, Xavier Pivot, Christophe Tournigand, et al.. (2007). Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Research and Treatment. 107(2). 275–279. 60 indexed citations
9.
Cals, L., X. Tchiknavorian, Nadine Dohollou, et al.. (2006). Non-pegylated liposomal doxorubicin and docetaxel as front line treatment in HER2-neu negative metastatic breast cancer: Safety and efficacy results. Journal of Clinical Oncology. 24(18_suppl). 10659–10659. 3 indexed citations
10.
11.
12.
Cunningham, David, John Zalcberg, Jean A. Maroun, et al.. (2002). Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancer. European Journal of Cancer. 38(4). 478–486. 52 indexed citations
13.
Belpomme, D, S. Gauthier, Éric Pujade-Lauraine, et al.. (2000). Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma. Annals of Oncology. 11(11). 1471–1476. 87 indexed citations
14.
Spaëth, D., et al.. (1997). Phase II studies of two trial regimens of topotecan as second-line single agent therapy in advanced breast cancer. European Journal of Cancer. 33. S158–S158. 5 indexed citations
15.
Chevallier, B, et al.. (1993). Epirubicin and Ifosfamide in Advanced Soft Tissue Sarcoma: A Phase II Study. Cancer Investigation. 11(2). 135–139. 18 indexed citations
16.
Velten, Markus, et al.. (1993). [Cancer of the breast in men. 106 cases].. PubMed. 22(10). 463–6. 8 indexed citations
17.
Pinon, G, Marie-Josèphe Goudier, Bertrand Coiffier, et al.. (1991). [Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group].. PubMed. 78(12). 1119–31. 3 indexed citations
18.
Lesaunier, F., et al.. (1986). Une tumeur rare: le chordome sacro-coccygien.. La Presse Médicale. 15(2). 79–79. 1 indexed citations
19.
Jacquillat, C, F Baillet, G Auclerc, et al.. (1984). Cancer du sein: chimiothérapie précédant le traitement loco-régional avec extension des indications du traitement conservateur.. Bulletin du Cancer. 71(4). 3 indexed citations
20.
Jacquillat, C, et al.. (1984). [Breast cancer: chemotherapy preceding locoregional treatment with extension of the indications for conservative treatment].. PubMed. 71(4). 354–60. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frances M. Palmieri Breakdown of academic impact, for papers by Sandeep Sehdev Breakdown of academic impact, for papers by Doris Augustin Breakdown of academic impact, for papers by Brian M.J. Cantwell Breakdown of academic impact, for papers by Paule Augereau Breakdown of academic impact, for papers by Tanja K. Froehlich Breakdown of academic impact, for papers by M. Clemons Breakdown of academic impact, for papers by Claudia Arce-Salinas Breakdown of academic impact, for papers by Rabih Said Breakdown of academic impact, for papers by Valeria Forestieri
Rankless by CCL
2026